ClinicalTrials.gg
Not yet recruitingNCT07391917ALExSEMUpdated Feb 18, 2026

Human Seminal Plasma Allergy: Quality of Life

An observational study in Allergic Reaction, sponsored by University Hospital, Angers. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by University Hospital, Angers · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
Female
01

Study summary

Human Seminal Plasma Allergy (HSPA) is a rare allergy with localized and/or generalized manifestations following exposure during unprotected sex. Its cause remains undetermined and is certainly underdiagnosed. It is an under-recognized cause of acute or chronic pain related to penetration and vaginal inflammation affecting sexually active women.

To date, no quality-of-life questionnaire specific to this condition exists to demonstrate its impact on the physical, mental, and sexual health of patients.

To try to highlight the suffering of these patients, non-specific sexual quality-of-life questionnaires exist and could be used, such as the "Female Sexual Function Index" (including questions on desire, arousal, and the ability to reach orgasm), but these do not address the sexual impact of psychological distress related to any pathology and do not assess the impact of HSPA-specific symptoms on sexuality. The symptoms of endometriosis can be compared to those of patients with HSPA due to chronic abdominopelvic pain that worsens during sexual intercourse, the psychological impact, and the potential effect on fertility.

A specific questionnaire exists for patients with endometriosis that documents these commonalities: the EHP-30. It is recognized as a specific and sensitive tool for measuring the quality of life of women with endometriosis in routine clinical practice. However, the EHP-30 questionnaire focuses on symptoms that are often chronic and persistent, even outside of sexual intercourse, whereas HSPA is characterized by acute episodes, sometimes spaced out and dependent on exposure to seminal fluid, making the tool less relevant for assessing the quality of life of patients with HSPA.

This study aims to evaluate and compare the measurement of quality of life in patients with HSPA using these different tools and a specific general question in order to describe quality of life in this population. This will also provide evidence to question the value of creating a questionnaire specific to the pathology.

Read the detailed description

After enrollment and questionnaire collection, relevant medical data are gathered from the medical record (data recorded during the consultation) :

  • General data: age, weight/height, number of children, desire for pregnancy, use of assisted reproductive technology, presence of a male dog or cat in the home
  • Comorbidities at diagnosis: atopic predisposition, allergies, asthma, eczema, urticaria, chronic rheumatological/urological/gynecological/psychiatric/other conditions
  • Characterization of the seminal fluid allergy: date of diagnosis, symptoms, number of partners with whom symptoms have occurred, time to onset of symptoms after exposure, duration of symptoms, results of allergy testing (prick tests, specific IgE, seminal fluid TB test)
  • Treatments offered and response (if applicable)
  • Outcome: Stability, improvement, worsening, recovery
02

Conditions studied

  • Allergic Reaction

Keywords

  • seminal fluid
  • allergy
  • sexuality
  • quality of life
  • Human Seminal Plasma Allergy (HSPA)
03

In context

Hypersensitivity

1,055 studies on the registry are indexed under Hypersensitivity; 149 are open to participants now.

This study's planned enrollment of 20 is below the median of 166 across 327 observational studies indexed under Hypersensitivity.

Browse Hypersensitivity studies →

Lead sponsor

University Hospital, Angers is the lead sponsor of 478 studies on the registry; 120 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Human Seminal Plasma Allergy (HSPA)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient
  • Treated at Angers University Hospital for Human Seminal Plasma Allergy during the period of interest (2010-2026)

Exclusion criteria

Exclusion Criteria:

  • Objecting to participating in the research
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • women with HSPA

    Measure of quality of life with different questionnaires

06

What researchers measure

Primary outcomes

  1. Overall Quality of life (WHOQOL-BREF)

    Measure of overall and domain-specific quality of life using the WHOQOL-BREF questionnaire (26 items). Unit of measurement: quality of life scores (overall score and scores for the 4 domains: physical health, psychological health, social relationships, environment), calculated from items rated on a Likert-type scale and converted into continuous scores (items scores between 4 and 20 ; higher scores = better quality of life).

    Time frame: 1 day

  2. Sexual Quality of life (FSFI)

    Measure of sexual quality of life using the Female Sexual Function Index (FSFI) questionnaire. Unit of measurement: total FSFI score and scores for individual domains (desire, arousal, lubrication, orgasm, satisfaction, pain), calculated from items rated on a Likert-type scale (higher scores = better sexual function). Total score of 2 to 36.

    Time frame: 1 day

  3. Quality of life and chronic gynecological condition (EHP30)

    Measure of the impact of endometriosis on quality of life using the Endometriosis Health Profile 30 (EHP 30) questionnaire as a reference for the chronic gynecological condition HSPA Unit of measurement: scores for domains (including pain, control and power, emotional well-being, social relationships, and work life), expressed on a scale of 0 to 4. Total score of 0 to 100 (0 = no impact/best quality of life, 100 = maximum impact on quality of life/worst quality of life).

    Time frame: 1 day

  4. Quality of life and HSPA

    Perceived quality of life related to the HSPA is measured using a general question: "How would you rate your overall quality of life in relation to your HSPA?" Unit of measurement: score on a numerical scale from 0 to 10 (0 = worst quality of life; 10 = perfect quality of life).

    Time frame: 1 day

Secondary outcomes

  1. Relationships between the scores

    The relationships between the different assessment tools (WHOQOL-BREF, FSFI, sections C to F of the EHP-30, and the general quality of life question) will be explored using Spearman correlations. Correlation coefficients will be visualized as a correlation matrix (corrplot) to identify potential links between the dimensions assessed by the different questionnaires.

    Time frame: 1 day

  2. Perception of validated questionnaires used

    An assessment of the questionnaire's relevance in evaluating the impact of the pathology on quality of life is included at the end of each questionnaire. Responses to these questions are given on a 4-point Likert scale. * Is the questionnaire relevant and sufficiently specific to the issues related to HSPA? (0 = Not at all relevant to 3 = Very relevant) * Do you feel that certain important dimensions of HSPA are neglected/not addressed? (0 = Strongly disagree to 3 = Strongly agree) * Do you think this questionnaire alone is sufficient to highlight the impact of HSPA on your quality of life? (0 = Strongly disagree to 3 = Strongly agree) * Do you find some questions and/or sub-scores unnecessary? (0 = Strongly disagree to 3 = Strongly agree)

    Time frame: 1 day

  3. Population

    Describe the characteristics of the population treated at the University Hospital of Angers for HSPA

    Time frame: 1 day

  4. Risk factors : BMI

    Current Body Mass Index (BMI): \< 20 kg/m²; 20-29 kg/m²; ≥ 30 kg/m²

    Time frame: 1 day

  5. Risk factors : age

    Age: 18-35 years; 35-50 years; \> 50 years

    Time frame: 1 day

  6. Risk factors : children

    Number of biological children

    Time frame: 1 day

  7. Risk factors : pregnancy

    Desire for pregnancy

    Time frame: 1 day

  8. Risk factors : eczema

    History of eczema

    Time frame: 1 day

  9. Risk factors : respiratory

    History of respiratory allergies and/or asthma

    Time frame: 1 day

07

Study locations

1 site
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07391917
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Feb 23, 2026 (estimated)
Primary completion
Aug 22, 2026 (estimated)
Completion
Aug 22, 2026 (estimated)
Last update
Feb 18, 2026

Study contacts

Martine MORISSET, Dr
Contact
mamorisset@chu-angers.fr
(0)2 41 35 35 51 ext. 33
Emeline BRUXELLE
Contact
emeline.bruxelle@gmail.com
(0)2 41 35 35 51 ext. 33
Martine MORISSET, Dr
principal investigator · University Hospital of Angers

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion